Pfizer Inc
NYSE: PFE
$25.65
+$0.52 (+2.1%)
Closing Price on November 22, 2024
PFE Articles
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
Published:
Moderna reported a 95.4% effectiveness rate for its COVID-19 vaccine. This is the second vaccine to hit more than 90% efficacy in the past week.
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, Beyond Meat, Biogen, Eli Lilly, Levi Strauss, Nvidia, Pfizer, Plug Power, Raytheon, Square and Wayfair.
Published:
Last Updated:
Pfizer and BioNTech stocks both exploded on Monday after these companies provided an update on their coronavirus vaccine.
Published:
The novel coronavirus has wiped out trillions of dollars in global output with more than 1 million deaths worldwide in 2020. With cases rising rapidly in the United States and in Europe, more...
Published:
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Caterpillar, Corning, DexCom, Enphase Energy, First Solar, Invesco, 3M, Microsoft, Pfizer and Wynn Resorts.
Published:
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday, and investors were not thrilled about this quarter for these two pharmaceutical giants.
Published:
This week will be perhaps the biggest week of earnings season, with many major names reporting, including Amazon, Facebook, Ford and Starbucks.
Published:
While other companies seem to be struggling with their coronavirus vaccines, Pfizer and BioNTech are just picking up speed. Pfizer’s CEO has provided an update on their COVID-19 vaccine.
Published:
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United...
Published:
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Published:
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, CSX, Dominion Energy, JPMorgan, NXP Semiconductors, ONEOK, Pfizer, Square, United Parcel Service and WPX Energy.
Published:
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Published:
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and back, which...
Published: